Oxford Immunotec, QIAGEN Report Settlement Of Patent Infringement Suit; All Claims Have Been Resolved; Oxford Has Granted QIAGEN Royalty-Free, Non-Exclusive License To All Current/Future Customers In Exchange For Lump-Sum Payment Of $27.5M